{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:12:24Z","timestamp":1790835144029,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.neuropharm.2011.04.001","type":"journal-article","created":{"date-parts":[[2011,4,19]],"date-time":"2011-04-19T03:48:30Z","timestamp":1303184910000},"page":"209-216","source":"Crossref","is-referenced-by-count":36,"title":["Enhanced effects of amphetamine but reduced effects of the hallucinogen, 5-MeO-DMT, on locomotor activity in 5-HT1A receptor knockout mice: Implications for schizophrenia"],"prefix":"10.1016","volume":"61","author":[{"given":"Maarten","family":"van den Buuse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Ruimschotel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria B.","family":"Risbrough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"Halberstadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2011.04.001_bib1","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.1523\/JNEUROSCI.18-14-05545.1998","article-title":"Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine","volume":"18","author":"Adams","year":"1998","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2011.04.001_bib2","first-page":"131","article-title":"Gating and habituation deficits in the schizophrenia disorders","volume":"3","author":"Braff","year":"1995","journal-title":"Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2011.04.001_bib3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00213-008-1205-9","article-title":"The absence of 5-HT1A receptors has minor effects on dopamine but not serotonin release evoked by MK-801 in mice prefrontal cortex","volume":"200","author":"Casta\u00f1\u00e9","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.04.001_bib4","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/sj.npp.1300678","article-title":"Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists","volume":"30","author":"Chartoff","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.04.001_bib5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00213-009-1604-6","article-title":"Psychotropic drug-induced locomotor hyperactivity and prepulse inhibition regulation in male and female aromatase knockout (ArKO) mice: role of dopamine D1 and D2 receptors and dopamine transporters","volume":"206","author":"Chavez","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.04.001_bib6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.brainres.2009.12.093","article-title":"The effect of estrogen on dopamine and serotonin receptor and transporter levels in the brain: autoradiography study","volume":"1321","author":"Chavez","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2011.04.001_bib7","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1476-5381.2008.00008.x","article-title":"The effect of \u2019two hit\u2019 neonatal and young-adult stress on dopaminergic modulation of prepulse inhibition and dopamine receptor density","volume":"156","author":"Choy","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2011.04.001_bib8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1515\/REVNEURO.1994.5.1.27","article-title":"Modulation of brain dopamine transmission by sex steroids","volume":"5","author":"Di Paolo","year":"1994","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2011.04.001_bib9","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0893-133X(99)00164-5","article-title":"Knockout mice reveal opposite roles for serotonin 1A and 1B receptors in prepulse inhibition","volume":"22","author":"Dulawa","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.04.001_bib10","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1124\/pr.59.07103","article-title":"5-HT receptor regulation of neurotransmitter release","volume":"59","author":"Fink","year":"2007","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2011.04.001_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF00426386","article-title":"Phencyclidine-induced locomotor activity in the rat is blocked by 6-hydroxydopamine lesion of the nucleus accumbens: comparisons to other psychomotor stimulants","volume":"82","author":"French","year":"1984","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.04.001_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002130100811","article-title":"Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review","volume":"156","author":"Geyer","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.04.001_bib13","series-title":"Neuropsychopharmacology - The Fifth Generation of Progress","first-page":"689","article-title":"Animal models relevant to schizophrenia disorders","author":"Geyer","year":"2002"},{"key":"10.1016\/j.neuropharm.2011.04.001_bib14","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1124\/jpet.109.162123","article-title":"Estrogen treatment blocks 8-OH-DPAT- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2, serotonin 5-HT1A, 5-HT2A or 5-HT7 receptors","volume":"333","author":"Gogos","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2011.04.001_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00213-008-1247-z","article-title":"Modification of the effects of 5-methoxy-N, N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors","volume":"201","author":"Halberstadt","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.04.001_bib16","doi-asserted-by":"crossref","unstructured":"Halberstadt, A. L., Koedood, L., Powell, S. B., Geyer, M. A. Differential contribution of serotonin receptors to the behavioral effects of indolamine hallucinogens in mice. J. Psychopharmacol. doi: 10.1177\/0269881110388326.","DOI":"10.1177\/0269881110388326"},{"key":"10.1016\/j.neuropharm.2011.04.001_bib17","series-title":"Handbook of the Behavioral Neurobiology of Serotonin","first-page":"621","article-title":"Serotonin and serotonin receptors in hallucinogen action","author":"Halberstadt","year":"2010"},{"key":"10.1016\/j.neuropharm.2011.04.001_bib18","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/npp.2009.29","article-title":"5-HT2A and 5-HT2C receptors exert opposing effects on locomotor activity in mice","volume":"34","author":"Halberstadt","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.04.001_bib19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0014-2999(95)00624-9","article-title":"R(+)-8\u2013OH-DPAT, a serotonin 1A receptor agonist, inhibits amphetamine-induced dopamine release in rat striatum and nucleus accumbens","volume":"287","author":"Ichikawa","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2011.04.001_bib20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0006-8993(99)02346-X","article-title":"The effect of serotonin 1A receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens","volume":"858","author":"Ichikawa","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2011.04.001_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0014-2999(76)90352-6","article-title":"Selective 6-OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats","volume":"40","author":"Kelly","year":"1976","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2011.04.001_bib22","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0006-8993(96)01111-0","article-title":"R(+)-8\u2013OH-DPAT, a 5-HT1A receptor agonist, inhibits amphetamine-induced serotonin and dopamine release in rat medial prefrontal cortex","volume":"743","author":"Kuroki","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2011.04.001_bib23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0006-3223(99)00067-0","article-title":"Increased dopamine transmission in schizophrenia: relationship to illness phases","volume":"46","author":"Laruelle","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2011.04.001_bib24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0028-3908(90)90001-8","article-title":"Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes","volume":"29","author":"McKenna","year":"1990","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2011.04.001_bib25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0079-6123(08)00909-6","article-title":"In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems","volume":"172","author":"Meltzer","year":"2008","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.neuropharm.2011.04.001_bib26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bbr.2008.05.016","article-title":"Does stimulation of 5-HT1A receptors improve cognition in schizophrenia?","volume":"195","author":"Meltzer","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2011.04.001_bib27","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0022-3565(24)38982-7","article-title":"Improving the treatment of schizophrenia: focus on serotonin (5-HT)1A receptors","volume":"295","author":"Millan","year":"2000","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2011.04.001_bib28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","article-title":"Hallucinogens","volume":"101","author":"Nichols","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2011.04.001_bib29","doi-asserted-by":"crossref","first-page":"10734","DOI":"10.1073\/pnas.95.18.10734","article-title":"Increased anxiety of mice lacking the serotonin 1A receptor","volume":"95","author":"Parks","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuropharm.2011.04.001_bib30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/BF00443425","article-title":"Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex","volume":"97","author":"Pierce","year":"1989","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.04.001_bib31","series-title":"Handbook of the Behavioral Neurobiology of Serotonin","first-page":"621","article-title":"Serotonin and schizophrenia","author":"Quednow","year":"2010"},{"key":"10.1016\/j.neuropharm.2011.04.001_bib32","doi-asserted-by":"crossref","first-page":"14476","DOI":"10.1073\/pnas.95.24.14476","article-title":"Serotonin receptor 1A knockout: an animal model of anxiety-related disorder","volume":"95","author":"Ramboz","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuropharm.2011.04.001_bib33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2011.04.001_bib34","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuropharm.2010.04.012","article-title":"Clozapine does not require 5-HT1A receptors to block the locomotor hyperactivity induced by MK-801: Clz and MK-801 in KO1A mice","volume":"59","author":"Scorza","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2011.04.001_bib35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/syn.890010203","article-title":"Dopamine receptors and the dopamine hypothesis of schizophrenia","volume":"1","author":"Seeman","year":"1987","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2011.04.001_bib36","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/schbul\/sbn009","article-title":"Cortical dopamine D2\/D3 receptors are a common site of action for antipsychotic drugs\u2013an original patient data meta-analysis of the SPECT and PET in\u00a0vivo receptor imaging literature","volume":"35","author":"Stone","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2011.04.001_bib37","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s12325-008-0102-2","article-title":"Serotonin 1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics","volume":"25","author":"Sumiyoshi","year":"2008","journal-title":"Adv. Ther."},{"key":"10.1016\/j.neuropharm.2011.04.001_bib38","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1176\/appi.ajp.158.10.1722","article-title":"Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment","volume":"158","author":"Sumiyoshi","year":"2001","journal-title":"Am. J.\u00a0Psychiatry"},{"key":"10.1016\/j.neuropharm.2011.04.001_bib39","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/BF02244616","article-title":"Amphetamine disruption of prepulse inhibition of acoustic startle is reversed by depletion of mesolimbic dopamine","volume":"100","author":"Swerdlow","year":"1990","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.04.001_bib40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0014-2999(03)01280-9","article-title":"5-HT1A receptor knockout mouse as a genetic model of anxiety","volume":"463","author":"Toth","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2011.04.001_bib41","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/schbul\/sbp132","article-title":"Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects","volume":"36","author":"van den Buuse","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2011.04.001_bib42","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1124\/jpet.106.113084","article-title":"Differential effects of antipsychotic drugs on serotonin-1A receptor mediated disruption of prepulse inhibition","volume":"320","author":"Van den Buuse","year":"2007","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2011.04.001_bib43","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1017\/S1461145709000388","article-title":"Neuregulin 1 hypomorphic mutant mice: enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation","volume":"12","author":"van den Buuse","year":"2009","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2011.04.001_bib44","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0079-6123(08)00911-4","article-title":"Serotonin\u2013dopamine interactions: implications for the design of novel therapeutic agents for psychiatric disorders","volume":"172","author":"Wood","year":"2008","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.neuropharm.2011.04.001_bib45","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/npp.2010.195","article-title":"The presynaptic component of the serotonergic system is required for clozapine\u2019s efficacy","volume":"36","author":"Yadav","year":"2011","journal-title":"Neuropsychopharmacology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390811001468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390811001468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T04:15:52Z","timestamp":1741148152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390811001468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":45,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0028390811001468"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2011.04.001","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}